While the activation of cGAS/STING may seem detrimental to tumour proliferation at first, cells carrying pathogenic variants (PVs) of BRCA1/2 genes simultaneously possess many mechanisms to suppress cGAS signaling and evade immune clearance, and hence they also possess greater immune evasion compared to sporadic breast cancers. This evidence concerns the gene BRCA1 and breast cancer.